Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Societal CDMO
Deal Size : Undisclosed
Deal Type : Agreement
Details : Ritalin LA is indicated for the treatment of attention deficit hyperactivity disorder. The product is an extended-release formulation of methylphenidate hydrochloride with a bi-modal release profile using the SODAS (Spheroidal Oral Drug Absorption System...
Product Name : Ritalin LA
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 05, 2022
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Societal CDMO
Deal Size : Undisclosed
Deal Type : Agreement